Skip to Content

Generic TriCor Availability

TriCor is a brand name of fenofibrate, approved by the FDA in the following formulation(s):

TRICOR (fenofibrate - tablet;oral)

  • Manufacturer: ABBVIE
    Approval date: November 5, 2004
    Strength(s): 48MG [RLD] [AB], 145MG [RLD] [AB]
  • Manufacturer: ABBVIE INC
    Approval date: September 4, 2001
    Strength(s): 54MG (discontinued) [RLD], 160MG (discontinued) [RLD]

Has a generic version of TriCor been approved?

A generic version of TriCor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to TriCor and have been approved by the FDA:

fenofibrate tablet;oral

  • Manufacturer: ALEMBIC PHARMS LTD
    Approval date: August 9, 2019
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: AMNEAL PHARMS LLC
    Approval date: February 9, 2018
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: May 5, 2016
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: CIPLA
    Approval date: December 15, 2016
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: GRAVITI PHARMS
    Approval date: March 18, 2020
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: HETERO LABS LTD III
    Approval date: July 12, 2016
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: LUPIN LTD
    Approval date: December 23, 2011
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: December 7, 2012
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: PRINSTON INC
    Approval date: August 28, 2018
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: SUN PHARM
    Approval date: September 7, 2017
    Strength(s): 48MG [AB], 145MG [AB]
  • Manufacturer: VALEANT PHARMS NORTH
    Approval date: April 5, 2012
    Strength(s): 48MG [AB], 145MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of TriCor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
    Patent 6,375,986
    Issued: April 23, 2002
    Inventor(s): Niels P.; Ryde & Stephen B.; Ruddy
    Assignee(s): Elan Pharma International Ltd.

    Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.

    Patent expiration dates:

    • September 21, 2020
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
      ✓ 
      Drug product
  • Nanoparticulate fibrate formulations
    Patent 7,276,249
    Issued: October 2, 2007
    Inventor(s): Ryde; Tuula & Gustow; Evan E. & Ruddy; Stephen B. & Jain; Rajeev & Patel; Rakesh & Wilkins; Michael John
    Assignee(s): Elan Pharma International, Ltd. Fournier Laboratories Ireland Ltd.

    The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.

    Patent expiration dates:

    • February 21, 2023
      ✓ 
      Drug product
  • Methods of treatment using nanoparticulate fenofibrate compositions
    Patent 7,320,802
    Issued: January 22, 2008
    Inventor(s): Ryde; Tuula & Gustow; Evan E. & Ruddy; Stephen B. & Jain; Rajeev & Patel; Rakesh & Wilkins; Michael John
    Assignee(s): Elan Pharma International, Ltd. Fournier Laboratories Ireland Ltd.

    The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.

    Patent expiration dates:

    • February 21, 2023
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.